Key result
Preperitoneal and visceral fat areas were the best predictors of steatohepatitis (R2 = 0.379) and fibrosis (R2 = 0.181), respectively, in patients with type 2 diabetes.
Why the study?
Do MRI-measured abdominal fat areas predict histopathologically determined steatosis, steatohepatitis, and fibrosis in patients with type 2 diabetes?
Cohort (n=66)
Do MRI-measured abdominal fat areas predict histopathologically determined steatosis, steatohepatitis, and fibrosis in patients with type 2 diabetes?
Effect estimate: R2 = 0.379 (preperitoneal fat for steatohepatitis); R2 = 0.181 (visceral fat for fibrosis)
p-value: p=≤0.002
Preperitoneal and visceral fat areas measured by MRI are potential non-invasive markers for detecting aggressive forms of non-alcoholic fatty liver disease in patients with type 2 diabetes.
May support MRI fat areas for non-invasive NAFLD risk stratification in T2D; leaves open prospective validation before practice change.
BACKGROUND AND AIM: Fat distribution may have prognostic value in the evaluation of non-alcoholic fatty liver disease. This study was conducted to evaluate associations of magnetic resonance imaging-measured abdominal fat areas with steatosis, steatohepatitis, and fibrosis, assessed histopathologically, in patients with type 2 diabetes. METHODS: This prospective study included 66 patients with type 2 diabetes (12 males, 54 females, age 26-68 years), without chronic liver disease of other causes. Axial dual-echo magnetic resonance images were acquired. Visceral, subcutaneous, and preperitoneal fat areas were measured using Osirix software. Liver biopsy specimens were obtained from all patients and examined histopathologically to evaluate steatosis, steatohepatitis, and fibrosis. Linear (for steatosis) and logistic (for steatohepatitis and fibrosis) regression models were fitted for the outcomes. R2 was used as a measure of how much model variance the predictors explained and to compare different predictors of the same outcome. RESULTS: Visceral and preperitoneal fat areas correlated well with histopathologically determined liver steatosis grade (both P = 0.004) and liver fibrosis (P = 0.008 and P = 0.037, respectively). All fat areas correlated well with steatohepatitis (P ≤ 0.002). Preperitoneal and visceral fat areas were the best predictors of steatohepatitis (R2 = 0.379) and fibrosis (R2 = 0.181), respectively. CONCLUSIONS: Visceral fat area was the best predictor of fibrosis in patients with type 2 diabetes. Preperitoneal fat area was the best predictor of steatohepatitis and is a potential new non-invasive marker for use in the screening of these patients to detect more aggressive forms of non-alcoholic fatty liver disease.
No takes yet. Share an insight, caveat, or question.
Parente et al. (2017) conducted a cohort in Type 2 diabetes and non-alcoholic fatty liver disease (n=66). Abdominal fat areas (visceral, subcutaneous, and preperitoneal) was evaluated on Histopathologically assessed steatosis, steatohepatitis, and fibrosis (R2 = 0.379 (preperitoneal fat for steatohepatitis); R2 = 0.181 (visceral fat for fibrosis), p=≤0.002). Preperitoneal and visceral fat areas were the best predictors of steatohepatitis (R2 = 0.379) and fibrosis (R2 = 0.181), respectively, in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: